Prognostic Impact of Parity in 493 Uterine Sarcoma Patients

Albrektsen, Grethe; Heuch, Ivar; Wik, Elisabeth; Salvesen, Helga B.

doi:10.1111/igc.0b013e3181aaa950

Cited by 14 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the rarity of uterine sarcomas, there are also only a limited number of published reports on the outcomes [11], and most of the outcome studies on uterine sarcomas have been based on small retrospective series from a single institution, which lack power to make significant conclusions [12], [13].…”

Section: Introductionmentioning

confidence: 99%

Nationwide Surveillance in Uterine Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in Taiwan

Huang

Chen

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

IntroductionUterine cancer was the most rapidly increasing malignancy and the second most common gynecologic malignancy in Taiwan.MethodsWe analyzed the secular trend of uterine cancer incidence and compare the survival of women with uterine carcinomas and uterine sarcomas in Taiwan. Data on women diagnosed with uterine cancer between 1979 and 2008 were obtained from the Taiwan cancer registry. Survival data were analyzed by using Kaplan-Meier and Cox proportional hazards regression methods.ResultsRecords of 11,558 women with uterine carcinomas and 1,226 women with uterine sarcomas were analyzed. The age-adjusted incidence rate of endometrioid adenocarcinoma increased from 0.83 per 100,000 women per year between 1979 and 1983 to 7.50 per 100,000 women per year between 2004 and 2008. The 5-year survival rate of women with endometrioid adenocarcinoma (83.2%) was higher than that for women with clear cell carcinoma (58.3%), serous carcinoma (54.4%), and carcinosarcoma (35.2%) (p<0.0001, log-rank test). The 5-year survival rates of women with low grade endometrial stromal sarcoma, endometrial stromal sarcoma, leiomyosarcoma (LMS), and adenosarcoma were 97.5%, 73.5%, 60.1%, and 77.2%, respectively (p<0.0001, log rank test). The histologic type of endometrioid adenocarcinoma, young age, and treatment period after 2000 were independent, favorable prognostic factors in women with uterine carcinomas by multivariate analysis. The histologic type of LMS, old age, and treatment period after 2000 were independent, poor prognostic factors in women with uterine sarcomas by multivariate analysis.ConclusionsAn increase over time in the number of patients with endometrioid adenocarcinomas was noted in this 30-year, nationwide, population-based study. Histologic type, age and treatment period were survival factors for uterine cancers. A more comprehensive assessment of uterine cancers and patient care should be undertaken on this increasingly common type of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Nationwide Surveillance in Uterine Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in Taiwan

Huang

Chen

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Ten percent of uterine carcinoma, which includes papillary serous carcinomas, clear cell carcinomas, and carcinosarcomas, are type II endometrial adenocarcinomas, which are highly aggressive, high-grade tumours that are not induced by estrogen and typically affect older, postmenopausal women (3,4,(7)(8)(9) . The three primary subtypes of uterine sarcoma are endometrial stromal sarcoma (ESS), leiomyosarcoma (LMS), and adenosarcoma (10) .…”

Section: Introductionmentioning

confidence: 99%

Treatment Outcomes of Uterine Carcinoma: A Single Institution Retrospective Study

Karim,

Fattah,

Ali

2023

JSMC

View full text Add to dashboard Cite

BackgroundEndometrial cancer has a lifetime risk of 2.6% for women living in industrialized countries and it is the most prevalent kind of cancer diagnosed in those regions. In terms of gynecologic cancer-related deaths, it ranks after ovarian and cervical cancer as the third most common cause. ObjectivesTo evaluate endometrial cancer patients’ long-term treatment outcomes, including disease-free survival and overall survival, as well as to pinpoint independent predictive markers. Materials and MethodsAt the Zhianawa Cancer Center, a retrospective analysis was conducted. All patients who had been referred for radiation therapy between March 2009 and January 2019 were included in the research, except those who had distant metastases. In the end, 89 patients were included. Using the Kaplan-Meier technique, overall survival and disease-free survival were calculated, and the significance of the variations across curves was evaluated using the log-rank test. ResultsAll patients underwent surgery, 96.6% received adjuvant radiotherapy, and 42.7% received concomitant chemotherapy. The 5-year and 10-year disease-free survivals were 62.9% and 56.2%, and the overall 5-year and 10-year survivals were 74.2% and 66.3% respectively. The statistically significant variables impacting disease-free survival were lymphovascular invasion and marginal status, and the only statistically significant prognostic variable affecting overall survival was the FIGO stage. ConclusionIn this analysis, we concluded that uterine cancer has a good prognosis, and its outcome was influenced by stage, lymphovascular space invasion, and surgical marginal status.

show abstract

Mesenchymal Tumors of the Uterus

Oliva¹,

Zaloudek²,

Soslow³

2018

Blaustein's Pathology of the Female Genital Tract

View full text Add to dashboard Cite

Prognostic Impact of Parity in 493 Uterine Sarcoma Patients

Abstract: Nulliparity seems to be associated with poorer prognosis in ESS patients; no independent prognostic impact of parity was seen among LS or CS patients. Further knowledge on underlying biological mechanisms may be valuable for improved treatment.

Cited by 14 publications

References 25 publications

Nationwide Surveillance in Uterine Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in Taiwan

Nationwide Surveillance in Uterine Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in Taiwan

Treatment Outcomes of Uterine Carcinoma: A Single Institution Retrospective Study

Mesenchymal Tumors of the Uterus

Contact Info

Product

Resources

About